Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Janus Living Inc. Class A-1 Common Stock (JAN) vs Kenvue Inc. Common Stock (KVUE) Price & Performance

Janus Living Inc. Class A-1 Common StockTrade
Kenvue Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Janus Living Inc. Class A-1 Common Stock vs Kenvue Inc. Common Stock — how do they compare? Janus Living Inc. Class A-1 Common Stock trades at $28.51 (market cap $6.76B), while Kenvue Inc. Common Stock trades at $18.12 (market cap $34.11B). The key difference: Kenvue Inc. Common Stock is far larger — about 5× Janus Living Inc. Class A-1 Common Stock's market cap, and Kenvue Inc. Common Stock pays the higher dividend (4.73%). Which is the better fit depends on your goals — on Pluang, investors hold Janus Living Inc. Class A-1 Common Stock for 0 Days and Kenvue Inc. Common Stock for 1 Days on average.

JANKVUE
Market Cap
$6.76B$34.11B
Volume
1,332,08227,388,811
Sector
Real EstateConsumer Staples
52-Week High
$31.76$19.83
52-Week Low
$22.88$14.11
Typical Hold Time
0 Days1 Days
Enterprise Value
$6.85B$41.62B
Dividend Yield
1.98%4.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Janus Living Inc. Class A-1 Common Stock

JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.

The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.

Kenvue Inc. Common Stock

Kenvue (KVUE) trades at $17.76, down 0.39% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $15.12B in 2025, with a net income margin of 10.76% and a P/E ratio of 20.89. Recent news highlights conditional EU approval for Kimberly-Clark's $40B acquisition of Kenvue, potentially impacting future operations and shareholder returns.

The outlook is mixed, with strong profitability and consistent dividend payments offering stability, but the pending acquisition introduces uncertainty. Risks include integration challenges and market volatility. Analyst consensus is a Hold with a $19.50 price target, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

JAN
100% Buy0% Sell
Avg holding period · 0 Days
KVUE

No sentiment data available yet.

Top news

Latest headlines on both assets

About Janus Living Inc. Class A-1 Common Stock

Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.

Read more on JAN →

About Kenvue Inc. Common Stock

Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.

Read more on KVUE →